Ma; Jian-xing

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ma; Jian-xing.The latest application filed is for "agonists of peroxisome proliferator-activated receptor alpha and methods of use".

Company Profile

4.8.14

Ma; Jian-xing - Edmond OK
Ma; Jian-xing - Oklahoma City OK

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Agonists of peroxisome proliferator-activated receptor alpha and methods of use Grant 11,447,452 - Duerfeldt , et al. September 20, 2	2022-09-20
PPAR.alpha. agonist compositions and methods of use Grant 11,369,575 - Ma , et al. June 28, 2	2022-06-28
Phenylquinoline compositions for treatment of ocular disorders and conditions Grant 11,337,968 - Ma , et al. May 24, 2	2022-05-24
Agonists Of Peroxisome Proliferator-activated Receptor Alpha And Methods Of Use App 20210024469 - Duerfeldt; Adam ; et al.	2021-01-28
PPARa AGONIST COMPOSITIONS AND METHODS OF USE App 20200297651 - Ma; Jian-xing ; et al.	2020-09-24
High isomerohydrolase activity mutants of human RPE65 Grant 10,494,619 - Ma , et al. De	2019-12-03
Phenylquinoline Compositions For Treatment Of Ocular Disorders And Conditions App 20190336491 - Ma; Jian-xing ; et al.	2019-11-07
Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof Grant 9,969,803 - Ma , et al. May 15, 2	2018-05-15
High Isomerohydrolase Activity Mutants Of Mammalian Rpe65 App 20170226490 - MA; JIAN-XING ; et al.	2017-08-10
Monoclonal Antibodies That Inhibit The Wnt Signaling Pathway and Methods of Production and Use Thereof App 20160229909 - Ma; Jian-xing ; et al.	2016-08-11
Monoclonal antibodies that inhibit the Wnt signaling pathway and methods of production and use thereof Grant 9,303,087 - Ma , et al. April 5, 2	2016-04-05
MONOCLONAL ANTIBODIES THAT INHIBIT THE Wnt SIGNALING PATHWAY AND METHODS OF PRODUCTION AND USE THEREOF App 20150017165 - Ma; Jian-xing ; et al.	2015-01-15
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof Grant 8,859,736 - Ma , et al. October 14, 2	2014-10-14
Compositions And Methods Of Inhibiting Retinal Degeneration App 20130225694 - Anderson; Robert E. ; et al.	2013-08-29
MONOCLONAL ANTIBODIES THAT INHIBIT THE Wnt SIGNALING PATHWAY AND METHODS OF PRODUCTION AND USE THEREOF App 20120045437 - Ma; Jian-Xing ; et al.	2012-02-23
Compounds useful in treating diabetic microvascular complications and age-related macular degeneration App 20070298997 - Ma; Jian-xing	2007-12-27
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same App 20060189534 - Ma; Jian-xing	2006-08-24
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same App 20050250694 - Ma, Jian-Xing	2005-11-10
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same App 20050143300 - Ma, Jian-Xing	2005-06-30
Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same App 20050130897 - Ma, Jian-xing	2005-06-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.